Erasca Q2 2021 Earnings Report

Reported financial results for the second quarter of 2021 and provided business updates.

Key Takeaways

Erasca reported a net loss of $28.2 million for the quarter ended June 30, 2021. The company nominated ERAS-3490 as its development candidate and dosed the first patient in HERKULES-1 study. Erasca completed a $345 million initial public offering in July 2021.

Nominated ERAS-3490 as development candidate from KRAS G12C inhibitor program in June 2021.

Dosed first patient in HERKULES-1 study in May 2021.

Completed $345 million initial public offering in July 2021.

Cash, cash equivalents, and investments were $198.7 million as of June 30, 2021.

EPS

-$1.2

Previous year: -$0.233